New ALS drug safety trial launches for Long-Term study
NCT ID NCT07571174
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests the long-term safety of a drug called LY4256984, given via spinal injection, in people with ALS. It includes 32 participants who completed an earlier study and will be followed for about 96 weeks. The main goal is to see how many people have serious side effects related to the drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LY4256984 (a drug given via spinal injection)
What this could lead to
If successful, this could show that LY4256984 is safe enough to continue testing as a potential treatment to slow ALS progression.
What could go wrong
This is a very early (Phase 1) study with only 32 participants. It focuses on safety, not effectiveness, so it may not lead to a working treatment. Spinal injections carry risks like back pain or infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Universitari de Bellvitge
NOT_YET_RECRUITINGL'Hospitalet de Llobregat, 08907, Spain
Contact
-
Hospital Universitari i Politecnic La Fe
NOT_YET_RECRUITINGValencia, 46026, Spain
Contact
-
McGill University Health Centre
RECRUITINGMontreal, H4A 3J1, Canada
Contact
-
Sunnybrook Research Institute
NOT_YET_RECRUITINGToronto, M4N 3M5, Canada
Contact
-
UZ Leuven
NOT_YET_RECRUITINGLeuven, 3000, Belgium
Contact
-
Universitaetsklinikum Ulm
NOT_YET_RECRUITINGUlm, 89081, Germany
Contact
-
Universitair Medisch Centrum Utrecht
NOT_YET_RECRUITINGUtrecht, 3584 CX, Netherlands
Contact
-
Universitätsklinikum Schleswig-Holstein
NOT_YET_RECRUITINGLübeck, 23538, Germany
Contact
-
Universitätsmedizin Rostock
NOT_YET_RECRUITINGRostock, 18147, Germany
Contact